Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States

CONCLUSION: Non-research payments to physician prescribers of PARP inhibitors from the manufacturers were significantly associated with increased prescriptions and Medicare expenditures for olaparib and rucaparib in the United States.PMID:38147713 | DOI:10.1016/j.ygyno.2023.12.011
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Source Type: research